MN SF1523

Health plan companies cannot charge higher co-payments, deductibles, or coinsurance for orally administered anticancer medications than for intravenously administered or injected cancer medications, effective January 1, 2017.

Health plan companies must indicate the coverage level for orally administered anticancer medication in their pharmacy benefit filings with the commissioner and cannot place such medications in the fourth tier of their pharmacy benefit.

Removes restrictive language regarding dependent coverage in small employer health plans, allowing coverage of dependent children regardless of residency and disabled dependents without limiting definitions.

Extends the external review request period for adverse health plan determinations from 6 months to 9 months from the date of the adverse determination.

Makes provisions from Minnesota Statutes 2012 applicable to grandfathered health plans for rating practices and dependent coverage requirements.